"Leprostatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions.
Descriptor ID |
D007917
|
MeSH Number(s) |
D27.505.954.122.085.777
|
Concept/Terms |
Leprostatic Agents- Leprostatic Agents
- Agents, Leprostatic
- Leprostatics
- Antileprotic Agents
- Agents, Antileprotic
|
Below are MeSH descriptors whose meaning is more general than "Leprostatic Agents".
Below are MeSH descriptors whose meaning is more specific than "Leprostatic Agents".
This graph shows the total number of publications written about "Leprostatic Agents" by people in this website by year, and whether "Leprostatic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 1 | 1 | 2 |
2018 | 2 | 3 | 5 |
2019 | 1 | 1 | 2 |
2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Leprostatic Agents" by people in Profiles.
-
An assessment of the reported impact of the COVID-19 pandemic on leprosy services using an online survey of practitioners in leprosy referral centres. Trans R Soc Trop Med Hyg. 2021 12 02; 115(12):1456-1461.
-
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med. 2020 12 30; 21(4):517-530.
-
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med. 2020 12 30; 21(4):611-614.
-
Will cases of leprosy reaction increase with COVID-19 infection? PLoS Negl Trop Dis. 2020 07; 14(7):e0008460.
-
Oro-facial manifestations in lepromatous leprosy patients in Central India: clinical findings from a cross-sectional study. Clin Oral Investig. 2020 Jun; 24(6):1981-1986.
-
Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opin Drug Metab Toxicol. 2019 May; 15(5):367-379.
-
Alternate anti-leprosy therapy for "Refractory Leprosy"! Dermatol Ther. 2019 03; 32(2):e12797.
-
Erythema Nodosum Leprosum as a Rare and Challenging Cause of Pyrexia of Unknown Origin. J Assoc Physicians India. 2018 04; 66(4):63-6.
-
Th17 Response of Borderline-Lepromatous Leprosy Inhibits Rash Manifestation of Dapsone Hypersensitivity Syndrome: Case Report. Am J Dermatopathol. 2018 Mar; 40(3):205-208.
-
Chronic Nodular Dermatosis: A Quiz. Acta Derm Venereol. 2018 Feb 07; 98(2):299-300.